AMENDMENTS TO THE CLAIMS

1-26. (Canceled)

27. (Currently Amended) A pharmaceutical composition consisting essentially of an

association of granulocyte colony stimulating factor (GCSF) and placental growth factor

(PIGF) as the active ingredient, in combination with suitable excipients and/or adjuvants,

wherein said association composition is able to mobilize peripheral blood progenitor cells

(PBPCs), thereby increasing the number of circulating white blood cells, circulating colony

forming blood cells or of circulating long term colony initiating blood cells.

28. (Previously Presented) The pharmaceutical composition according to claim 27 containing

recombinant hGCSF and recombinant hPlGF.

29. (Previously Presented) The pharmaceutical composition according to claim 27 formulated

for parenteral administration.

30. (Currently Amended) A method for increasing the number of circulating white blood

cells, circulating colony forming blood cells or of circulating long term colony initiating

blood cells, consisting of comprising the sole step of administering either separately or

simultaneously to a patient having undergone a procedure selected from the group

consisting of: tumor chemo-radio therapy, autologous stem cells transplantation, allogeneic

stem cells transplantation and myelosuppressive chemo-therapy in-need of such a treatment

an effective amount of both granulocyte colony stimulating factor (GCSF) and placental

growth factor (PIGF) in combination with suitable excipients and/or adjuvants.

31. (Cancelled)

32. (Currently Amended) The method according to claim 30, wherein said granulocyte colony

stimulating factor (GCSF) and placental growth factor (PIGF) are administered separately

or simultaneously by a parenteral route.

3

DRN/MHE/cjd

Application No. 10/565,903 Reply to Office Action of September 18, 2008 Amendment dated February 17, 2009

- 33. (Currently Amended) The method according to claim 30 comprising consisting the sole step-of administering either simultaneously or separately from 10 to 150 μg/kg of said granulocyte colony stimulating factor (GCSF) and from 10 to 300 μg/kg of said placental growth factor (PIGF) in combination with suitable excipients and/or adjuvants.
- 34. (Currently Amended) The method according to claim 30 comprising the consisting of sole step of administering simultaneously said granulocyte colony stimulating factor (GCSF) and said placental growth factor (PIGF) in combination with suitable excipients and/or adjuvants.
- 35. (Currently Amended) The method according to claim 34 comprising consisting of the sole step of administering a pharmaceutical composition consisting essentially of: an association of granulocyte colony stimulating factor (GCSF) and placental growth factor (PIGF) as the active ingredients, in combination with suitable excipients and/or adjuvants.
- 36. (Currently Amended) The method according to claim 30, wherein said colony stimulating factor (GCSF) and placental growth factor (PlGF) are administered either sequentially or separately at intervalsdaily.